MedTrace Logo

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

NCT07028970 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-06-19

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.

Conditions

Interventions

OTHER

No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )

This study is observational study and all participants will be obsreved with no intervention.

Sponsors & Collaborators

  • Nanjing IASO Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jian Li, PhD · Peking Union Medical College Hospital

  • Juan Du, PhD · RenJi Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2040-12-31
Completion
2043-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07028970 on ClinicalTrials.gov